A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Background BI 836826 is a chimeric mouse–human monoclonal antibody directed against human CD37, a transmembrane protein expressed on mature B lymphocytes. This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determine the maximum tolerated dose (MTD), safety/tolerability, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Balzarotti, Monica, Magagnoli, Massimo, Canales, Miguel Ángel, Corradini, Paolo, Grande, Carlos, Sancho, Juan-Manuel, Zaja, Francesco, Quinson, Anne-Marie, Belsack, Valérie, Maier, Daniela, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279964/
https://www.ncbi.nlm.nih.gov/pubmed/33523334
http://dx.doi.org/10.1007/s10637-020-01054-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279964/
https://www.ncbi.nlm.nih.gov/pubmed/33523334
http://dx.doi.org/10.1007/s10637-020-01054-6

Ejemplares similares